What's new

Filters: policy
x
Newsroom

Twitter

Videos

Photos

20160128 EGA Regulatory and Scientific Affairs Conferenc

Positioning Statements on Physician-led Switching for Biosimilar Medicines

27 April 2019

Policy

Positioning Statements on Physician-led Switching for Biosimilar Medicines BIOSIMILAR MEDICINES […]

Read more

Medicines For Europe Country Specific Market Access Policies

24 May 2018

Policy

Open

Position paper on Best Procurement Practices

28 April 2018

Policy

Open

IGBA position on identification of biological, including biosimilar medicines (2018 update of facts & figures)

20 April 2018

Policy

Open

Life Science Industry Coalition Position paper

14 December 2017

Policy

Open

Position Paper: for an ambitious EU industrial strategy

24 October 2017

Policy

Open

SPC manufacturing waiver

24 October 2017

Policy

SME Intergroup Conclusions – Boosting SMEs through the SPC Waiver […]

Read more

Fighting counterfeit medicines in Europe: the effect on access to medicines

14 September 2017

Policy

The implementation of the Falsified Medicines Directive, and its Delegated […]

Read more

US FDA Advisory committee hears first-hand about the decade of EU experience with biosimilar medicines use

13 July 2017

Policy

Medicines for Europe Director General Adrian van de Hoven participated […]

Read more

Medicines for Europe Country Specific Market Access Policies

23 May 2017

Policy

Open

Subscribe to our newsletter